Helen is a Clinical Scientist & Research Associate within the Immunisation, Hepatitis & Blood Safety Department at the Communicable Infectious Disease Surveillance Centre, Public Health England, London.
Helen set-up the National Register of Hepatitis C Infections with a known date of acquisition, and leads a programme of work on hepatitis C natural history and burden.
During her time at PHE, and its predecessor organisation the Health Protection Agency, Helen has published a number of papers in the field of hepatitis C natural history and disease burden. Helen leads and edits the national ‘Hepatitis C in the UK’ report, which summaries current knowledge about hepatitis C infection in the UK and monitors the progress of national action plans in tackling this infection.
Last year, our Hepatitis C in the UK report, focusing on elimination, showed the first fall in deaths from severe hep C-related liver disease in over a decade. Our latest report suggests that this decline has been sustained for a second …
Since new direct acting antiviral drugs have become available, the initial focus has understandably been on their role in averting severe hepatitis C-related liver disease and preventing the early death that can result from this.
We heard welcome news from NICE recently that a new drug, which effectively treats more genotypes of hepatitis C, has been recommended for use in the NHS. NICE concluded that the once-daily tablet sofosbuvir-velpatasvir was both clinically and cost-effective, and …
We need to find people with advanced hepatitis C virus related liver disease and provide treatment in order to prevent them dying prematurely from this chronic infection or needing liver transplants or progressing to liver cancer. This is because in …
